


Product Name	: DCC-2618
Synonyms	: Ripretinib;DCC2618
Cat No.	: M11875
CAS Number	: 1442472-39-0
Molecular Formula	: C ₂₄ H ₂₁ BrFN ₅ O ₂
Formula Weight	: 510.37
Chemical Name	: 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
Description	 <p>DCC-2618 (Ripretinib, DCC2618) is a potent, oral inhibitor of singly and doubly mutated KIT with IC₅₀ of WT (IC₅₀=4 nM), V654A (8 nM), T670I (18 nM), D816H (5 nM), D816V; also inhibits PDGFRα/β, KDR and cFMS, robustly inhibits exon 17, exon 9/13, exon 9/14, and exon 9/17 KIT mutants, as well as exon 11/17 KIT mutants; inhibits wild type and mutant KIT phosphorylation in cancer cells, demonstrates the potential to treat KIT mutant-driven cancers including GIST, systemic mastocytosis, AML, or melanoma. Gastric Cancer Phase 3 Clinical</p>
Pathway	: Angiogenesis
Target	: c-Kit
Receptor	: c-Kit
Solubility	: DMSO : 45 mg/mL 88.17 mM
SMILES	: <chem>CCN1C2=CC(=NC=C2C=C(C1=O)C3=CC(=C(C=C3Br)F)NC(=O)NC4=CC=CC=C4)NC</chem>
Storage	: (-20°C)
Stability	: ≥ 2 years
Reference	:

1. Mathias A Schneeweiss, et al. Blood 2016 128:1965. | 2. Cancer Discov. 2017 Feb;7(2):121-122. doi: 10.1158/2159-8290.